Background: DNA topoisomerase I and II (Topo I and Topo II) are nuclear enzymes that regulate the topological structure of DNA in eukaryotic cells by transiently breaking and rejoining DNA strands. Eukaryotic topoisomerases are capable of relaxing both positive and negative supercoils, whereas prokaryotic topo-isomerases relax only negative supercoils. DNA topoisomerases play a role in DNA replication, recombination and transcription, and have been identified as targets of numerous anticancer drugs. Topo I, an ubiquitously expressed, soluble enzyme, acts by introducing a transient break in one strand of DNA, while Topo II acts by making a transinet double-strand break. Topo II is encoded by two different genes to generate two distinct isoforms that are designated Topo IIα and Topo IIβ. Topo IIα and Topo IIβ are largely homologous at their N-terminal three quarters, however the C-terminal segments are considerably divergent, suggesting that these regions may mediate different cellular functions and account for the observed differential tissue expression patterns of the two isoforms.
Description: Rabbit polyclonal to Topoisomerase I
Immunogen: KLH conjugated synthetic peptide derived from Topoisomerase I
Specificity: ·Reacts with Human, Mouse and Rat.
·Isotype: IgG
Application: ·Western blotting: 1/100-500. Predicted Mol wt: 90 kDa;
·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;
·Immunocytochemistry/Immunofluorescence: 1/100;
·Immunoprecipitation: 1/50;
·ELISA: 1/500;
·Optimal working dilutions must be determined by the end user.
